Pediatric Dermatology

Latest News

Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA
Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA

December 2nd 2024

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Pediatric Melanoma in Review: Providing Considerations for Dermatologists
Pediatric Melanoma in Review: Providing Considerations for Dermatologists

November 22nd 2024

Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights
Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights

November 17th 2024

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD
Off-Treatment Remission Achieved with Dupilumab for Pediatric AD

November 4th 2024

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds
Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds

October 24th 2024

© 2024 MJH Life Sciences

All rights reserved.